iSpecimen Adds Acutis Diagnostics to Marketplace Platform to Support Oncology and Infectious Disease Research
April 13 2022 - 7:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a
global online biospecimen marketplace that enables life scientists
to search across a federated network of healthcare providers for
biospecimens needed for medical research, today announced that it
added Acutis Diagnostics (“Acutis”), a clinical diagnostics
laboratory, to its platform as a laboratory services provider.
Through the Acutis relationship, iSpecimen will now offer
sequencing services to its research community that can help
researchers better understand genetic mutations and their impact on
diseases such as COVID-19 and cancer.
Cancer and COVID-19 are currently the second and
third leading causes of death in the U.S., respectively. As
such, biospecimen samples for these diseases, along with
corresponding sequencing data, remain in high demand among
researchers who are working on the development of novel diagnostics
and therapeutics that could lead to lifesaving medical
interventions. By offering sequencing services for specimens
procured on iSpecimen’s platform, researchers can now identify
desired samples and receive corresponding sequencing data from a
single source instead of vetting and contracting with external
sequencing service provider partners.
“This important initiative between Acutis and
iSpecimen highlights our ongoing efforts to advance research in the
areas of oncology and COVID-19 today,” said Jibreel Sarij, Acutis
CEO. “Furthermore, our investment in personnel, technology and
other essential resources allows us to provide high-quality, whole
genome sequencing to iSpecimen for COVID-19 remnants, tumor
samples, and other biospecimens of interest.”
“Adding Acutis to the iSpecimen Marketplace
ecosystem enables the platform to become even more of a
full-service, one-stop-shop for researchers looking to find highly
sought-after samples and genetic information for their medical
research,” added Dr. Christopher Ianelli, M.D., Ph.D., iSpecimen
Founder and CEO. “iSpecimen continues to prioritize expanding its
proprietary network and platform to ensure that researchers all
over the world can easily obtain invaluable biospecimen samples
necessary to propel their work forward.”
About iSpecimeniSpecimen Inc.
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
About Acutis Diagnostics Acutis
is a vertically integrated, research-driven healthcare company that
bridges the gap between emerging science and commercialization
while providing the highest quality life sciences services and
products. This combination allows Acutis to seamlessly integrate
standard of care testing with the needs of biopharma, resulting in
a client-centric delivery model for both the clinical and research
markets. For more information, please visit www.acutis.com.
Forward Looking StatementsThis
press release may contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," "believe," "estimate" and "continue" or similar
words. You should read statements that contain these words
carefully because they discuss future expectations and plans, which
contain projections of future results of operations or financial
condition or state other forward-looking information.
Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risk factors contained in the Company's filings with the Securities
and Exchange Commission, which are available for review at
www.sec.gov. Forward-looking statements speak only as of the date
they are made. New risks and uncertainties arise over time, and it
is not possible for the Company to predict those events or how they
may affect the Company. If a change to the events and circumstances
reflected in the Company's forward-looking statements occurs, the
Company's business, financial condition and operating results may
vary materially from those expressed in the Company's
forward-looking statements.
Readers are cautioned not to put undue reliance
on forward-looking statements, and the Company assumes no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information, please
contact:
iSpecimen Media ContactsRaquel
Cona / Shana MarinoKCSA Strategic
CommunicationsiSpecimen@kcsa.com
iSpecimen Investor
ContactAllison SossKCSA Strategic
CommunicationsiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2023 to Apr 2024